Jefferies and Leerink Partners are bookrunners; Needham, FBR to assist
By Devika Patel
Knoxville, Tenn., April 3 - Corium International, Inc. said it priced its $52 million initial public sale of stock with a $7.8 million greenshoe. The deal was announced March 3.
The company will sell 6.5 million common shares at $8.00 per share.
Jefferies LLC and Leerink Partners LLC are the joint bookrunning managers.
Proceeds will be used for Phase 2 clinical trials for MicroCor hPTH(1-34) and Corplex Tamsulosin, to scale up production capability for the company's MicroCor products, to advance the MicroCor technology, to repurchase common shares and for working capital and other general corporate purposes.
The biopharmaceutical company is based in Menlo Park, Calif. The company intends to list its common stock on the Nasdaq under the symbol "CORI."
| Issuer: | Corium International, Inc.
|
| Issue: | Common stock
|
| Amount: | $52 million
|
| Greenshoe: | $7.8 million
|
| Shares: | 6.5 million
|
| Price: | $8.00
|
| Warrants: | No
|
| Bookrunners: | Jefferies LLC and Leerink Partners LLC
|
| Co-managers: | Needham & Co., LLC and FBR Capital Markets & Co.
|
| Announcement date: | March 3
|
| Pricing date: | April 3
|
| Stock exchange: | Nasdaq: CORI
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
